knowledge -WSS

knowledge

author：Wikipedia 2025-09-06 05:03:23 - browse：842

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Colorectal cancer study finds potential in overlooked immune cell

WSS

Stroke deaths set to near 10 million globally by 2050

AI can decode, harness the power of the humane immune system

AI can decode, harness the power of the humane immune system

Idaho abortion case may prompt more restrictions in other states

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

FDA authorizes Novavax’s updated Covid

hotspot

knowledge

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Analysis of telehealth claims data suggest service duplication

Anesthesiologist group: stop taking Ozempic before surgery

The SUPPORT Act is critical to fighting the opioid crisis

Jerome Adams on the need for new antivirals for Covid

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Medical leaders decry Supreme Court decision on affirmative action

HHS names first

Psychedelics group wrestles with new pharma identity

Biotech reporter’s notebook: A sunnier mood at JPM 2024

explore

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Analysis of telehealth claims data suggest service duplication

Senate panel eyes new effort on drug shortages

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Stroke deaths set to near 10 million globally by 2050

Colorectal cancer study finds potential in overlooked immune cell

Wikipedia

explore

leisure time

explore